Head and neck cancer: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett |
||
| Line 9: | Line 9: | ||
===Cetuximab=== | ===Cetuximab=== | ||
[[Cetuximab]] | [[Cetuximab]] chimeric recombinant monoclonal [[antibody]] that blocks [[epidermal growth factor receptor]] (EGFR).<ref name="pmid18784104">{{cite journal| author=Haddad RI, Shin DM| title=Recent advances in head and neck cancer. | journal=N Engl J Med | year= 2008 | volume= 359 | issue= 11 | pages= 1143-54 | pmid=18784104 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18784104 | doi=10.1056/NEJMra0707975 }} </ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18784104 | doi=10.1056/NEJMra0707975 }} </ref>In the major [[randomized control trial]], the percentage of cells that are EGFR positive did not seen to predict the response to cetuximab.<ref name="pmid18784101">{{cite journal| author=Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al.| title=Platinum-based chemotherapy plus cetuximab in head and neck cancer. | journal=N Engl J Med | year= 2008 | volume= 359 | issue= 11 | pages= 1116-27 | pmid=18784101 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18784101 | doi=10.1056/NEJMoa0802656 }} </ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 08:57, 31 May 2010
Cause / etiology
Human papillomavirus (HPV) is a risk factor for oropharyngeal cancer.[1]
Treatment
Head and Neck Cancer treatment information from the National Cancer Institute's Physician Data Query
Salivary Gland Cancer treatment information from the National Cancer Institute's Physician Data Query
Cetuximab
Cetuximab chimeric recombinant monoclonal antibody that blocks epidermal growth factor receptor (EGFR).[1]In the major randomized control trial, the percentage of cells that are EGFR positive did not seen to predict the response to cetuximab.[2]
References
- ↑ 1.0 1.1 Haddad RI, Shin DM (2008). "Recent advances in head and neck cancer.". N Engl J Med 359 (11): 1143-54. DOI:10.1056/NEJMra0707975. PMID 18784104. Research Blogging.
- ↑ Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. (2008). "Platinum-based chemotherapy plus cetuximab in head and neck cancer.". N Engl J Med 359 (11): 1116-27. DOI:10.1056/NEJMoa0802656. PMID 18784101. Research Blogging.